December 15th 2022
A biologic from Germany offers a new treatment option for a number of dermatologic conditions.
December 8th 2021
June 22nd 2021
Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability ApplicationApril 26th 2021
Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
IL-17, IL-23 Inhibitors May Outperform Older Biologics, Oral TherapiesJanuary 21st 2021
Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.
Safety profiles differentiate conventional therapiesNovember 11th 2020
In a recent study, psoriasis drugs showed widely variable drug survival rates, owing to differences in safety, efficacy, patient satisfaction and other factors. However, concerns linger over potential to cause long-term cumulative organ toxicity.
Systemic psoriasis therapies not age-dependentNovember 10th 2020
Comorbidities, co-medication, organ impairment, functional deterioration and frailty make treatment plans challenging for older psoriasis patients. However, these patients should not be precluded but will require more extensive evaluation and assessment, according to a recent study.
Therapeutic, management considerations with biologicsJuly 24th 2020
Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
Bimekizumab phase 3 data reflect rapid, durable responseJune 29th 2020
Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.
With newer biologics consistently posting PASI improvements greater than 90%, dermatologists need to consider other factors when selecting a treatment. However, nuanced differences between the same drug class could be teased out, one expert says.
Topical guidelines will provide real-world guidanceMay 19th 2020
The latest set of guidelines for psoriasis being developed by the American Academy of Dermatology and the National Psoriasis Foundation will stress patient education and the need to align treatment strategies with patient lifestyles.
Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapiesApril 24th 2020
The latest American Academy of Dermatology-National Psoriasis Foundation phototherapy guidelines incorporate several advances in efficacy, safety and patient convenience that were unavailable a decade ago.
Biologic guidelines for psoriasis let providers chooseApril 24th 2020
When it comes to biologic drugs, the latest joint American Academy of Dermatology-National Psoriasis Foundation guidelines are less prescriptive than descriptive, offering a comprehensive discussion on the facts of each biologic to inform physicians’ selections.
Combining psoriasis topicals yields unpredictable resultsMarch 24th 2020
Dermatologists often combine multiple topical agents on their own, and have been doing so for many years. However, extemporaneous compounding of psoriasis topical agents may not necessarily yield what dermatologists anticipate.
IL-23 inhibitors may offer psoriasis patients longer-lasting resultsFebruary 19th 2020
With extended remissions, high safety and favorable dosing schedules, interleukin (IL)-23 inhibitors are well-suited for a variety of patients with psoriasis, says an expert who spoke at the South Beach Symposium
Phase 3 results show risankizumab outperforms secukinumabJanuary 17th 2020
Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.